In the randomised, Ph III IMpower150 study, first-line treatment (tx) with A + B + carboplatin and paclitaxel (CP) significantly prolonged PFS and OS compared with B + CP in patients (pts) with non-squamous NSCLC, including those with EGFR mutations….Exploratory analyses included OS in pts with EGFR mutations, pts with sensitising EGFR mutations (exon 19 deletions or L858R mutations) and pts with sensitising EGFR mutations who received prior tyrosine kinase inhibitors (TKIs)....With ≈ 20 additional months of follow-up, ABCP continued to show an OS benefit vs BCP in pts with sensitising EGFR mutations, including those who had prior tx failure with TKIs.